The Global Transcatheter Aortic Valve Replacement Market size is expected to reach $8 billion by 2028, rising at a market growth of 7.5% CAGR during the forecast period.
Open heart surgery, called transcatheter aortic valve replacement, uses a far less invasive technique to replace an enlarged aortic valve. Aortic stenosis is managed with its help. The aortic valve's partial closure, which restricts blood flow, is known as aortic stenosis. Blood is transported from the heart to the body's many organs via the enormous aorta artery. The surgical replacement of the aortic valve (SAVR) is not an option for these high-risk individuals, and it cannot be performed. Due to the significant risk of open heart surgery for the elderly, they fall within the category of high-risk patients.
New aortic valves are implanted during a transcatheter aortic valve replacement (TAVR) procedure to restore the aortic valve's blood-flow capabilities. Transcatheter aortic valve implantation becomes more necessary as aortic stenosis grows more widespread. The rise in aortic stenosis prevalence, the rise in demand for different TAVR operations, and improvements in transcatheter aortic valve implantation technology are the main reasons behind the expansion of the transcatheter aortic valve replacement market.
Also, the geriatric population is growing, which drives the market for TAVR because older people are more susceptible to aortic stenosis. In addition, the market is growing due to improvements in TAVR valve technology and increased awareness of early diagnosis. The spike in interest in minimally or non-invasive procedures due to the multiple advantages these surgeries offer is one of the major drivers accelerating market growth in the upcoming years.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Edwards Lifesciences Corporation, MicroPort Scientific Corporation, LivaNova PLC, TTK Healthcare Limited, Meril Life Science Private Limited, JenaValve Technology, Inc., and Bracco S.p.A.
Open heart surgery, called transcatheter aortic valve replacement, uses a far less invasive technique to replace an enlarged aortic valve. Aortic stenosis is managed with its help. The aortic valve's partial closure, which restricts blood flow, is known as aortic stenosis. Blood is transported from the heart to the body's many organs via the enormous aorta artery. The surgical replacement of the aortic valve (SAVR) is not an option for these high-risk individuals, and it cannot be performed. Due to the significant risk of open heart surgery for the elderly, they fall within the category of high-risk patients.
New aortic valves are implanted during a transcatheter aortic valve replacement (TAVR) procedure to restore the aortic valve's blood-flow capabilities. Transcatheter aortic valve implantation becomes more necessary as aortic stenosis grows more widespread. The rise in aortic stenosis prevalence, the rise in demand for different TAVR operations, and improvements in transcatheter aortic valve implantation technology are the main reasons behind the expansion of the transcatheter aortic valve replacement market.
Also, the geriatric population is growing, which drives the market for TAVR because older people are more susceptible to aortic stenosis. In addition, the market is growing due to improvements in TAVR valve technology and increased awareness of early diagnosis. The spike in interest in minimally or non-invasive procedures due to the multiple advantages these surgeries offer is one of the major drivers accelerating market growth in the upcoming years.
COVID-19 Impact Analysis
As the surgical procedure was temporarily delayed and was not an emergency, the COVID-19 outbreak has had a significant negative impact on the market for aortic valve replacement devices. This resulted from the significant infection risk in the healthcare sector, which patients with heart-related diseases were susceptible to. However, the need for heart disease diagnostics and treatment will certainly increase due to the elimination of COVID-19 restrictions and an increase in patient visits to hospitals and clinics, driving the TAVR procedure market growth over the projection period. Additionally, market innovation keeps improving the growth prospects.Market Growth Factors
Increased preference for minimally-invasive procedures
The main benefit of transcatheter valve replacement surgery is that it may be performed through tiny incisions, preserving all of the chest bones. Patients who have not been given the choice of a valve replacement procedure can also benefit from this course of treatment. Compared to surgical valve replacement, these procedures necessitate a shorter hospital stay for the patients. The market for transcatheter aortic valve replacement is anticipated to expand in the near future as a result of the rising demand for minimally invasive procedures.Grown occurrence of aortic valve stenosis & valvular diseases
The demand for AVR devices is increasing as AS, and valvular disorders become more prevalent. These ailments have the potential to cause fatal complications like heart failure, stroke, and death. To stop these disorders from getting worse and lower the risk of consequences, early diagnosis and treatment are essential. The transcatheter aortic valve replacement market's sales revenue is therefore being driven by a rise in awareness of the significance of early detection and treatment of AS and valvular disorders.
Market Restraining Factors
Risks involved in aortic valve replacement
Over 25% of patients experience irregular heartbeat (arrhythmia) following an aortic valve replacement, but this condition typically disappears over time. However, 1% to 2% of people will require the fitting of a pacemaker to regulate their heartbeat. Up to 5% of persons with kidney issues experience short-term kidney dysfunction following surgery. Temporary dialysis could be required in a few situations. A major procedure, replacing the aortic valve, can occasionally result in deadly consequences. These issues with the aortic valve replacement may restrict the patients from undergoing the procedure, restraining market growth over the forecast period.Implantation Procedure Outlook
By Implantation procedure, the transcatheter aortic valve replacement market is segmented into transfemoral, transapical, and transaortic. The transapical segment garnered a significant revenue share in the transcatheter aortic valve replacement market in 2021. The transapical approach's proximity to the aortic valve and left ventricular apex enhances operator mobility while device implantation and permits the use of sheaths with larger diameters. Innovative transapical devices have been created and developed by several companies.Material Outlook
On the basis of material, the transcatheter aortic valve replacement market is bifurcated into stainless steel, nitinol, cobalt chromium, and others. In 2021, the nitinol segment witnessed the highest revenue share in the transcatheter aortic replacement market. Nickel and titanium are almost equally distributed in the alloy known as titanium. Due to its unique qualities, which include its lack of magnetism, biocompatibility, flexibility, and fatigue resistance, it is frequently used in most TAVR devices. This enables medical devices in minimally invasive surgeries, as well as implants, to provide improved outcomes, thereby boosting segment growth.Mechanism Outlook
Based on mechanism, the transcatheter aortic valve replacement market is fragmented into balloon-expanding valve and self-expanding valve. In 2021, the balloon-expanding valve segment dominated the transcatheter aortic valve replacement. Balloon-expanding valves make it simpler to access the coronary arteries since they are intra-annular, non-repositionable, and have a reduced stent frame profile. A horizontal aorta (aortic angulation >60°), for example, makes it easier to implant a valve in patients with difficult vascular architecture since the delivery mechanism is more steerable than that of the self-expanding device. Also, the segment's expansion is being fueled by new product launches.End-use Outlook
By end-use, the transcatheter aortic valve replacement market is categorized into hospitals, ambulatory surgical centers, others. The ambulatory surgery centers segment recorded a remarkable revenue share in the transcatheter aortic valve replacement market in 2021. Since the TAVR is a novel procedure replacing open surgery, the number of ambulatory surgery facilities is increasing in developed regions. In addition, because TAVR is a less difficult procedure that takes less time to recuperate, it can be performed in surgery centers. This supports the segment's growth.Regional Outlook
Region wise, the transcatheter aortic valve replacement market is analyzed across North America, Europe, Asia Pacific and LAMEA. The North America region led the transcatheter aortic valve replacement market by generating the highest revenue share in 2021. The market is expanding rapidly in North America due to several factors, including the rising prevalence of valvular illnesses and greater public awareness of the advantages of transcatheter aortic valve replacement over traditional surgical methods. In addition, an important factor in the market's growth is the region's growing geriatric population.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Edwards Lifesciences Corporation, MicroPort Scientific Corporation, LivaNova PLC, TTK Healthcare Limited, Meril Life Science Private Limited, JenaValve Technology, Inc., and Bracco S.p.A.
Strategies Deployed in Transcatheter Aortic Valve Replacement Market
- Jan-2023: Abbott Laboratories received a U.S. Food and Drug Administration Approval for Navitor. The Navitor is the company's latest-generation transcatheter aortic valve implantation (TAVI) system. This TAVI System is used to treat people with extreme aortic stenosis who are at increased risk for open-heart surgery.
- Dec-2022: Abbott Laboratories unveiled the Navitor in India. The Navitor is a latest-generation transcatheter aortic valve implantation (TAVI) system. With this launch, Abbott Laboratories is making the minimally invasive device known for people in India with extreme aortic stenosis who are at increased surgical risk.
- Sep-2022: Edwards Lifesciences Corporation launched SAPIEN 3 Ultra RESILIA valve. The SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve system is meant for the comfort of aortic stenosis in patients with symptomatic heart disease due to extreme native calcific aortic stenosis. This launch is followed by U.S. Food and Drug Administration (FDA) approval.
- Sep-2022: Medtronic Plc launched the Evolut FX TAVR system. The new Evolut FX TAVR system is the newest-generation, self-expanding transcatheter aortic valve replacement (TAVR) system. Additionally, Evolut FX counts unique features to the current Evolut platform to improve ease of use and predictable valve deployment for physicians. Moreover, the complete commercial release of the Evolut FX system obeys U.S. Food and Drug Administration (FDA) approval as well
- Feb-2022: Boston Scientific Corporation took over Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as sheaths and dilators used to support catheter-based left-heart procedures. Through this acquisition, Boston Scientific Corporation would be able to combine the Baylis platforms with its current structural heart and electrophysiology offerings. Moreover, this step would further strengthen Boston's position within the highest-growth cardiology markets.
- Sep-2021: Abbott Laboratories received the U.S. Food and Drug Administration Approval for Portico with FlexNav transcatheter aortic valve replacement (TAVR) system. This new transcatheter aortic valve replacement (TAVR) system is used to treat people with symptomatic, intense aortic stenosis who are at elevated risk for open-heart surgery.
- Aug-2021: Medtronic plc received a U.S. Food and Drug Administration (FDA) approval for Evolut FX TAVR system. The new Evolut FX is a self-expanding transcatheter aortic valve replacement (TAVR) system. This new TAVR system is crafted to improve ease of use and deliver superb precision and command throughout the procedure.
- Sep-2020: Boston Scientific Corporation unveiled the ACURATE neo2 Aortic Valve System in Europe. The ACURATE neo2 Aortic Valve System is a next-generation transcatheter aortic valve implantation (TAVI) technology which is the latest platform crafted with several features to enhance the clinical performance of the original ACURATE neo platform.
- Apr-2019: Boston Scientific Corporation received the U.S. Food and Drug Administration Approval for the LOTUS Edge Aortic Valve System. The new LOTUS Edge Aortic Valve System is a transcatheter aortic valve replacement (TAVR) technology that is approved for patients with extreme aortic stenosis who are at increased risk for surgical valve replacement via open heart surgery.
- Aug-2018: Boston Scientific Corporation took over Claret Medical, Inc., a privately-held company that has developed and commercialized the Sentinel Cerebral Embolic Protection System. Through this acquisition, Boston Scientific would be able to increase momentum and enhance the patient approach to the valuable technology, named Sentinel Cerebral Embolic Protection System.
Scope of the Study
By Material
- Nitinol
- Stainless Steel
- Cobalt-Chromium
- Others
By Implantation Procedure
- Transfemoral
- Transapical
- Transaortic
By Mechanism
- Balloon-expanding Valve
- Self-expanding Valve
By End-use
- Hospitals
- Ambulatory Surgical Centers
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Medtronic PLC
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- MicroPort Scientific Corporation
- LivaNova PLC
- TTK Healthcare Limited
- Meril Life Science Private Limited
- JenaValve Technology, Inc.
- Bracco S.p.A
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Transcatheter Aortic Valve Replacement Market, by Material
1.4.2 Global Transcatheter Aortic Valve Replacement Market, by Implantation Procedure
1.4.3 Global Transcatheter Aortic Valve Replacement Market, by Mechanism
1.4.4 Global Transcatheter Aortic Valve Replacement Market, by End-use
1.4.5 Global Transcatheter Aortic Valve Replacement Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Transcatheter Aortic Valve Replacement Market
Chapter 4. Global Transcatheter Aortic Valve Replacement Market by Material
4.1 Global Nitinol Market by Region
4.2 Global Stainless Steel Market by Region
4.3 Global Cobalt-Chromium Market by Region
4.4 Global Others Market by Region
Chapter 5. Global Transcatheter Aortic Valve Replacement Market by Implantation Procedure
5.1 Global Transfemoral Market by Region
5.2 Global Transapical Market by Region
5.3 Global Transaortic Market by Region
Chapter 6. Global Transcatheter Aortic Valve Replacement Market by Mechanism
6.1 Global Balloon-expanding Valve Market by Region
6.2 Global Self-expanding Valve Market by Region
Chapter 7. Global Transcatheter Aortic Valve Replacement Market by End-use
7.1 Global Hospitals Market by Region
7.2 Global Ambulatory Surgical Centers Market by Region
7.3 Global Others Market by Region
Chapter 8. Global Transcatheter Aortic Valve Replacement Market by Region
8.1 North America Transcatheter Aortic Valve Replacement Market
8.1.1 North America Transcatheter Aortic Valve Replacement Market by Material
8.1.1.1 North America Nitinol Market by Country
8.1.1.2 North America Stainless Steel Market by Country
8.1.1.3 North America Cobalt-Chromium Market by Country
8.1.1.4 North America Others Market by Country
8.1.2 North America Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.1.2.1 North America Transfemoral Market by Country
8.1.2.2 North America Transapical Market by Country
8.1.2.3 North America Transaortic Market by Country
8.1.3 North America Transcatheter Aortic Valve Replacement Market by Mechanism
8.1.3.1 North America Balloon-expanding Valve Market by Country
8.1.3.2 North America Self-expanding Valve Market by Country
8.1.4 North America Transcatheter Aortic Valve Replacement Market by End-use
8.1.4.1 North America Hospitals Market by Country
8.1.4.2 North America Ambulatory Surgical Centers Market by Country
8.1.4.3 North America Others Market by Country
8.1.5 North America Transcatheter Aortic Valve Replacement Market by Country
8.1.5.1 US Transcatheter Aortic Valve Replacement Market
8.1.5.1.1 US Transcatheter Aortic Valve Replacement Market by Material
8.1.5.1.2 US Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.1.5.1.3 US Transcatheter Aortic Valve Replacement Market by Mechanism
8.1.5.1.4 US Transcatheter Aortic Valve Replacement Market by End-use
8.1.5.2 Canada Transcatheter Aortic Valve Replacement Market
8.1.5.2.1 Canada Transcatheter Aortic Valve Replacement Market by Material
8.1.5.2.2 Canada Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.1.5.2.3 Canada Transcatheter Aortic Valve Replacement Market by Mechanism
8.1.5.2.4 Canada Transcatheter Aortic Valve Replacement Market by End-use
8.1.5.3 Mexico Transcatheter Aortic Valve Replacement Market
8.1.5.3.1 Mexico Transcatheter Aortic Valve Replacement Market by Material
8.1.5.3.2 Mexico Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.1.5.3.3 Mexico Transcatheter Aortic Valve Replacement Market by Mechanism
8.1.5.3.4 Mexico Transcatheter Aortic Valve Replacement Market by End-use
8.1.5.4 Rest of North America Transcatheter Aortic Valve Replacement Market
8.1.5.4.1 Rest of North America Transcatheter Aortic Valve Replacement Market by Material
8.1.5.4.2 Rest of North America Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.1.5.4.3 Rest of North America Transcatheter Aortic Valve Replacement Market by Mechanism
8.1.5.4.4 Rest of North America Transcatheter Aortic Valve Replacement Market by End-use
8.2 Europe Transcatheter Aortic Valve Replacement Market
8.2.1 Europe Transcatheter Aortic Valve Replacement Market by Material
8.2.1.1 Europe Nitinol Market by Country
8.2.1.2 Europe Stainless Steel Market by Country
8.2.1.3 Europe Cobalt-Chromium Market by Country
8.2.1.4 Europe Others Market by Country
8.2.2 Europe Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.2.2.1 Europe Transfemoral Market by Country
8.2.2.2 Europe Transapical Market by Country
8.2.2.3 Europe Transaortic Market by Country
8.2.3 Europe Transcatheter Aortic Valve Replacement Market by Mechanism
8.2.3.1 Europe Balloon-expanding Valve Market by Country
8.2.3.2 Europe Self-expanding Valve Market by Country
8.2.4 Europe Transcatheter Aortic Valve Replacement Market by End-use
8.2.4.1 Europe Hospitals Market by Country
8.2.4.2 Europe Ambulatory Surgical Centers Market by Country
8.2.4.3 Europe Others Market by Country
8.2.5 Europe Transcatheter Aortic Valve Replacement Market by Country
8.2.5.1 Germany Transcatheter Aortic Valve Replacement Market
8.2.5.1.1 Germany Transcatheter Aortic Valve Replacement Market by Material
8.2.5.1.2 Germany Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.2.5.1.3 Germany Transcatheter Aortic Valve Replacement Market by Mechanism
8.2.5.1.4 Germany Transcatheter Aortic Valve Replacement Market by End-use
8.2.5.2 UK Transcatheter Aortic Valve Replacement Market
8.2.5.2.1 UK Transcatheter Aortic Valve Replacement Market by Material
8.2.5.2.2 UK Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.2.5.2.3 UK Transcatheter Aortic Valve Replacement Market by Mechanism
8.2.5.2.4 UK Transcatheter Aortic Valve Replacement Market by End-use
8.2.5.3 France Transcatheter Aortic Valve Replacement Market
8.2.5.3.1 France Transcatheter Aortic Valve Replacement Market by Material
8.2.5.3.2 France Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.2.5.3.3 France Transcatheter Aortic Valve Replacement Market by Mechanism
8.2.5.3.4 France Transcatheter Aortic Valve Replacement Market by End-use
8.2.5.4 Russia Transcatheter Aortic Valve Replacement Market
8.2.5.4.1 Russia Transcatheter Aortic Valve Replacement Market by Material
8.2.5.4.2 Russia Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.2.5.4.3 Russia Transcatheter Aortic Valve Replacement Market by Mechanism
8.2.5.4.4 Russia Transcatheter Aortic Valve Replacement Market by End-use
8.2.5.5 Spain Transcatheter Aortic Valve Replacement Market
8.2.5.5.1 Spain Transcatheter Aortic Valve Replacement Market by Material
8.2.5.5.2 Spain Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.2.5.5.3 Spain Transcatheter Aortic Valve Replacement Market by Mechanism
8.2.5.5.4 Spain Transcatheter Aortic Valve Replacement Market by End-use
8.2.5.6 Italy Transcatheter Aortic Valve Replacement Market
8.2.5.6.1 Italy Transcatheter Aortic Valve Replacement Market by Material
8.2.5.6.2 Italy Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.2.5.6.3 Italy Transcatheter Aortic Valve Replacement Market by Mechanism
8.2.5.6.4 Italy Transcatheter Aortic Valve Replacement Market by End-use
8.2.5.7 Rest of Europe Transcatheter Aortic Valve Replacement Market
8.2.5.7.1 Rest of Europe Transcatheter Aortic Valve Replacement Market by Material
8.2.5.7.2 Rest of Europe Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.2.5.7.3 Rest of Europe Transcatheter Aortic Valve Replacement Market by Mechanism
8.2.5.7.4 Rest of Europe Transcatheter Aortic Valve Replacement Market by End-use
8.3 Asia Pacific Transcatheter Aortic Valve Replacement Market
8.3.1 Asia Pacific Transcatheter Aortic Valve Replacement Market by Material
8.3.1.1 Asia Pacific Nitinol Market by Country
8.3.1.2 Asia Pacific Stainless Steel Market by Country
8.3.1.3 Asia Pacific Cobalt-Chromium Market by Country
8.3.1.4 Asia Pacific Others Market by Country
8.3.2 Asia Pacific Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.3.2.1 Asia Pacific Transfemoral Market by Country
8.3.2.2 Asia Pacific Transapical Market by Country
8.3.2.3 Asia Pacific Transaortic Market by Country
8.3.3 Asia Pacific Transcatheter Aortic Valve Replacement Market by Mechanism
8.3.3.1 Asia Pacific Balloon-expanding Valve Market by Country
8.3.3.2 Asia Pacific Self-expanding Valve Market by Country
8.3.4 Asia Pacific Transcatheter Aortic Valve Replacement Market by End-use
8.3.4.1 Asia Pacific Hospitals Market by Country
8.3.4.2 Asia Pacific Ambulatory Surgical Centers Market by Country
8.3.4.3 Asia Pacific Others Market by Country
8.3.5 Asia Pacific Transcatheter Aortic Valve Replacement Market by Country
8.3.5.1 China Transcatheter Aortic Valve Replacement Market
8.3.5.1.1 China Transcatheter Aortic Valve Replacement Market by Material
8.3.5.1.2 China Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.3.5.1.3 China Transcatheter Aortic Valve Replacement Market by Mechanism
8.3.5.1.4 China Transcatheter Aortic Valve Replacement Market by End-use
8.3.5.2 Japan Transcatheter Aortic Valve Replacement Market
8.3.5.2.1 Japan Transcatheter Aortic Valve Replacement Market by Material
8.3.5.2.2 Japan Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.3.5.2.3 Japan Transcatheter Aortic Valve Replacement Market by Mechanism
8.3.5.2.4 Japan Transcatheter Aortic Valve Replacement Market by End-use
8.3.5.3 India Transcatheter Aortic Valve Replacement Market
8.3.5.3.1 India Transcatheter Aortic Valve Replacement Market by Material
8.3.5.3.2 India Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.3.5.3.3 India Transcatheter Aortic Valve Replacement Market by Mechanism
8.3.5.3.4 India Transcatheter Aortic Valve Replacement Market by End-use
8.3.5.4 South Korea Transcatheter Aortic Valve Replacement Market
8.3.5.4.1 South Korea Transcatheter Aortic Valve Replacement Market by Material
8.3.5.4.2 South Korea Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.3.5.4.3 South Korea Transcatheter Aortic Valve Replacement Market by Mechanism
8.3.5.4.4 South Korea Transcatheter Aortic Valve Replacement Market by End-use
8.3.5.5 Singapore Transcatheter Aortic Valve Replacement Market
8.3.5.5.1 Singapore Transcatheter Aortic Valve Replacement Market by Material
8.3.5.5.2 Singapore Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.3.5.5.3 Singapore Transcatheter Aortic Valve Replacement Market by Mechanism
8.3.5.5.4 Singapore Transcatheter Aortic Valve Replacement Market by End-use
8.3.5.6 Malaysia Transcatheter Aortic Valve Replacement Market
8.3.5.6.1 Malaysia Transcatheter Aortic Valve Replacement Market by Material
8.3.5.6.2 Malaysia Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.3.5.6.3 Malaysia Transcatheter Aortic Valve Replacement Market by Mechanism
8.3.5.6.4 Malaysia Transcatheter Aortic Valve Replacement Market by End-use
8.3.5.7 Rest of Asia Pacific Transcatheter Aortic Valve Replacement Market
8.3.5.7.1 Rest of Asia Pacific Transcatheter Aortic Valve Replacement Market by Material
8.3.5.7.2 Rest of Asia Pacific Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.3.5.7.3 Rest of Asia Pacific Transcatheter Aortic Valve Replacement Market by Mechanism
8.3.5.7.4 Rest of Asia Pacific Transcatheter Aortic Valve Replacement Market by End-use
8.4 LAMEA Transcatheter Aortic Valve Replacement Market
8.4.1 LAMEA Transcatheter Aortic Valve Replacement Market by Material
8.4.1.1 LAMEA Nitinol Market by Country
8.4.1.2 LAMEA Stainless Steel Market by Country
8.4.1.3 LAMEA Cobalt-Chromium Market by Country
8.4.1.4 LAMEA Others Market by Country
8.4.2 LAMEA Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.4.2.1 LAMEA Transfemoral Market by Country
8.4.2.2 LAMEA Transapical Market by Country
8.4.2.3 LAMEA Transaortic Market by Country
8.4.3 LAMEA Transcatheter Aortic Valve Replacement Market by Mechanism
8.4.3.1 LAMEA Balloon-expanding Valve Market by Country
8.4.3.2 LAMEA Self-expanding Valve Market by Country
8.4.4 LAMEA Transcatheter Aortic Valve Replacement Market by End-use
8.4.4.1 LAMEA Hospitals Market by Country
8.4.4.2 LAMEA Ambulatory Surgical Centers Market by Country
8.4.4.3 LAMEA Others Market by Country
8.4.5 LAMEA Transcatheter Aortic Valve Replacement Market by Country
8.4.5.1 Brazil Transcatheter Aortic Valve Replacement Market
8.4.5.1.1 Brazil Transcatheter Aortic Valve Replacement Market by Material
8.4.5.1.2 Brazil Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.4.5.1.3 Brazil Transcatheter Aortic Valve Replacement Market by Mechanism
8.4.5.1.4 Brazil Transcatheter Aortic Valve Replacement Market by End-use
8.4.5.2 Argentina Transcatheter Aortic Valve Replacement Market
8.4.5.2.1 Argentina Transcatheter Aortic Valve Replacement Market by Material
8.4.5.2.2 Argentina Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.4.5.2.3 Argentina Transcatheter Aortic Valve Replacement Market by Mechanism
8.4.5.2.4 Argentina Transcatheter Aortic Valve Replacement Market by End-use
8.4.5.3 UAE Transcatheter Aortic Valve Replacement Market
8.4.5.3.1 UAE Transcatheter Aortic Valve Replacement Market by Material
8.4.5.3.2 UAE Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.4.5.3.3 UAE Transcatheter Aortic Valve Replacement Market by Mechanism
8.4.5.3.4 UAE Transcatheter Aortic Valve Replacement Market by End-use
8.4.5.4 Saudi Arabia Transcatheter Aortic Valve Replacement Market
8.4.5.4.1 Saudi Arabia Transcatheter Aortic Valve Replacement Market by Material
8.4.5.4.2 Saudi Arabia Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.4.5.4.3 Saudi Arabia Transcatheter Aortic Valve Replacement Market by Mechanism
8.4.5.4.4 Saudi Arabia Transcatheter Aortic Valve Replacement Market by End-use
8.4.5.5 South Africa Transcatheter Aortic Valve Replacement Market
8.4.5.5.1 South Africa Transcatheter Aortic Valve Replacement Market by Material
8.4.5.5.2 South Africa Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.4.5.5.3 South Africa Transcatheter Aortic Valve Replacement Market by Mechanism
8.4.5.5.4 South Africa Transcatheter Aortic Valve Replacement Market by End-use
8.4.5.6 Nigeria Transcatheter Aortic Valve Replacement Market
8.4.5.6.1 Nigeria Transcatheter Aortic Valve Replacement Market by Material
8.4.5.6.2 Nigeria Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.4.5.6.3 Nigeria Transcatheter Aortic Valve Replacement Market by Mechanism
8.4.5.6.4 Nigeria Transcatheter Aortic Valve Replacement Market by End-use
8.4.5.7 Rest of LAMEA Transcatheter Aortic Valve Replacement Market
8.4.5.7.1 Rest of LAMEA Transcatheter Aortic Valve Replacement Market by Material
8.4.5.7.2 Rest of LAMEA Transcatheter Aortic Valve Replacement Market by Implantation Procedure
8.4.5.7.3 Rest of LAMEA Transcatheter Aortic Valve Replacement Market by Mechanism
8.4.5.7.4 Rest of LAMEA Transcatheter Aortic Valve Replacement Market by End-use
Chapter 9. Company Profiles
9.1 Abbott Laboratories
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Product Launches and Product Expansions:
9.1.5.2 Approvals and Trials:
9.1.6 SWOT Analysis
9.2 Medtronic PLC
9.2.1 Company overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Product Launches and Product Expansions:
9.2.5.2 Approvals and Trials:
9.2.6 SWOT Analysis
9.3 Boston Scientific Corporation
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Product Launches and Product Expansions:
9.3.5.2 Acquisition and Mergers:
9.3.5.3 Approvals and Trials:
9.4 Edwards Lifesciences Corporation
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Product Launches and Product Expansions:
9.5 MicroPort Scientific Corporation
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.6 LivaNova PLC
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expense
9.7 TTK Healthcare Limited
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.8 Meril Life Sciences Private Limited
9.8.1 Company Overview
9.9 JenaValve Technology, Inc.
9.9.1 Company Overview
9.10. Bracco S.p.A.
9.10.1 Company Overview
Companies Mentioned
- Abbott Laboratories
- Medtronic PLC
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- MicroPort Scientific Corporation
- LivaNova PLC
- TTK Healthcare Limited
- Meril Life Science Private Limited
- JenaValve Technology, Inc.
- Bracco S.p.A
Methodology
LOADING...
